TABLE 1.
C. dubliniensis isolates investigated by MLST analysisc
| Isolate | Country of origin | Yr of isolation | Underlying patient condition | Sample | MLST cladea | ITS genotype | Cd25 fingerprint group | Reference(s) or source |
|---|---|---|---|---|---|---|---|---|
| CD36b | Ireland | 1988 | HIV pos | Oral | 1 | 1 | I | 21, 51 |
| CD06033b | Ireland | 2006 | CF | Sputum | 1 | 1 | ND | This study |
| CD06031 | Ireland | 2006 | CF | Sputum | 1 | 1 | ND | This study |
| CD060213 | Ireland | 2006 | CF | Sputum | 1 | 1 | ND | This study |
| CD06041 | Ireland | 2006 | CF | Sputum | 1 | 1 | ND | This study |
| CD06038b | Ireland | 2006 | CF | Sputum | 1 | 1 | ND | This study |
| CD06045 | Ireland | 2006 | CF | Sputum | 1 | 1 | ND | This study |
| CD06037b | Ireland | 2006 | CF | Sputum | 2 | 2 | ND | This study |
| CD06036b | Ireland | 2006 | CF | Sputum | 2 | 2 | ND | This study |
| CD060215b | Ireland | 2006 | CF | Sputum | 3 | 3 | ND | This study |
| CD604b | France | 2000 | HIV asymptomatic | Throat | 1 | 1 | ND | This study |
| CD603b | France | 2000 | HIV asymptomatic | Throat | 1 | 1 | ND | This study |
| CM1b | Australia | 1991 | HIV pos | Oral | 1 | 1 | I | 21, 51 |
| SA105 | Saudi Arabia | 2002 | Diabetes | Oral | 1 | 1 | I | 4 |
| SA115 | Saudi Arabia | 2002 | Diabetes | Oral | 1 | 1 | I | 4 |
| SA116 | Saudi Arabia | 2002 | Diabetes | Oral | 1 | 1 | I | 4 |
| SA108b | Saudi Arabia | 2002 | Diabetes | Oral | 3 | 3 | III | 4 |
| SA100b | Saudi Arabia | 2002 | Leukemia | Oral | 3 | 3 | III | 4 |
| SA121b | Saudi Arabia | 2002 | S/P renal tx | Oral | 3 | 4 | III | 4 |
| Eg202 | Egypt | 2002 | Cancer | Oral | 3 | 4 | III | 4 |
| Eg203 | Egypt | 2002 | Cancer | Oral | 1 | 1 | I | 4 |
| Eg204 | Egypt | 2002 | Cancer | Oral | 1 | 1 | I | 4 |
| Eg207 | Egypt | 2002 | Diabetes | Oral | 3 | 4 | III | 4 |
| p6785b | Israel | 1999 | HIV neg | Urine | 3 | 3 | II | 4, 39 |
| p7276b | Israel | 1999 | HIV neg | Respiratory tract | 3 | 3 | II | 4 |
| p7718 | Israel | 1999 | HIV neg | Wound | 3 | 4 | III | 4, 21 |
| CD71 | Argentina | 1994 | HIV pos | Oral | 1 | 1 | I | 21, 48 |
| CD98923 | India | 1998 | HIV pos | Oral | 1 | 1 | I | 2 |
| B1324 | United States | 1998 | NA | Tongue | 1 | 1 | ND | This study |
| B341 | United States | 1998 | NA | Throat | 1 | 1 | ND | This study |
| PM6-2 | Chile | 2006 | NA | NA | 1 | 1 | ND | This study |
| P2 | Switzerland | 1993 | HIV pos | Oral | 1 | 1 | I | 4, 21 |
| 1504 | Slovakia | 2005 | NA | Tonsular swab | 1 | 1 | ND | 32 |
| 8882 | Slovakia | 2005 | Congenital hydrocephalus | Tonsular swab | 1 | 1 | ND | 32 |
| 9097 | Slovakia | 2005 | Leukemia | Tonsular swab | 1 | 1 | ND | 32 |
| 966/3(1)b | Slovakia | 2005 | NA | Sputum | 1 | 1 | ND | 32 |
| 966/3(2) | Slovakia | 2005 | NA | Sputum | 1 | 1 | ND | 32 |
| CCY29-177-1 | Slovakia | 2005 | Pelvic organ inflammation | Cervical swab | 1 | 1 | ND | 32 |
| MLNIH0479 | Thailand | 2005 | Leukemia | Blood | 1 | 1 | ND | 13 |
| MLNIH0720 | Thailand | 2005 | TB, anemia, diabetes | Oral | 1 | 1 | ND | 13 |
| 49831 | Japan | 2005 | Anemia | Sputum | 2 | 2 | ND | 13 |
| IFM49883 | Japan | 2005 | NA | NA | 2 | 2 | ND | 13 |
| IFM0492 | Thailand | 2005 | Cancer | Blood | 1 | 1 | ND | 13 |
| IFM49832 | Japan | 2005 | Diabetes | Sputum | 1 | 1 | ND | 13 |
| Can4 | Canada | 1996 | HIV pos | Oral | 2 | 2 | II | 21, 38 |
| CD539 | United Kingdom | 1994 | AIDS | Oral | 2 | 2 | II | 21, 38 |
| CBS2747 | The Netherlands | 1952 | HIV neg | Sputum | 2 | 2 | II | 21, 31 |
| CD514 | Ireland | 1995 | HIV neg | Oral | 3 | 3 | II | 21 |
| CD519 | Ireland | 1997 | AIDS | Oral | 3 | 3 | II | 21 |
| CD75004 | United Kingdom | 1975 | Diabetes | Oral | 2 | 2 | II | 21, 38 |
a
MLST clades assigned in the present study.
b
Isolate included in assessment of sequence stability and MLST reproducibility.
c
HIV pos, HIV infected; HIV neg, HIV negative; CF, cystic fibrosis; S/P renal tx, stage post-renal transplantation; NA, not available; TB, tuberculosis; ND, not determined.